{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:09:25Z","timestamp":1793729365253,"version":"4.6.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2023A1515030038"],"award-info":[{"award-number":["2023A1515030038"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373433"],"award-info":[{"award-number":["82373433"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473417"],"award-info":[{"award-number":["82473417"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82403606"],"award-info":[{"award-number":["82403606"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Funct Integr Genomics"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s10142-026-01884-2","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T04:49:17Z","timestamp":1778906957000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["An integrated molecular classification system identifies distinct prognostic clusters of non-muscle-invasive bladder cancer"],"prefix":"10.1007","volume":"26","author":[{"given":"Kezhi","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haihua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengpeng","family":"Gui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziran","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheyu","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiyu","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihao","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,16]]},"reference":[{"key":"1884_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"1884_CR2","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s40779-024-00569-w","volume":"11","author":"H Zi","year":"2024","unstructured":"Zi H, Liu M-Y, Luo L-S, Huang Q, Luo P-C, Luan H-H et al (2024) Global burden of benign prostatic hyperplasia, urinary tract infections, urolithiasis, bladder cancer, kidney cancer, and prostate cancer from 1990 to 2021. Mil Med Res 11:64. https:\/\/doi.org\/10.1186\/s40779-024-00569-w","journal-title":"Mil Med Res"},{"key":"1884_CR3","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","volume":"71","author":"M Babjuk","year":"2017","unstructured":"Babjuk M, B\u00f6hle A, Burger M, Capoun O, Cohen D, Comp\u00e9rat EM et al (2017) EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol 71:447\u2013461. https:\/\/doi.org\/10.1016\/j.eururo.2016.05.041","journal-title":"Eur Urol"},{"key":"1884_CR4","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","volume":"77","author":"A Kamoun","year":"2020","unstructured":"Kamoun A, de Reyni\u00e8s A, Allory Y, Sj\u00f6dahl G, Robertson AG, Seiler R et al (2020) A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur Urol 77:420\u2013433. https:\/\/doi.org\/10.1016\/j.eururo.2019.09.006","journal-title":"Eur Urol"},{"key":"1884_CR5","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.eururo.2014.01.006","volume":"66","author":"RS Svatek","year":"2014","unstructured":"Svatek RS, Hollenbeck BK, Holm\u00e4ng S, Lee R, Kim SP, Stenzl A et al (2014) The economics of bladder cancer: costs and considerations of caring for this disease. Eur Urol 66:253\u2013262. https:\/\/doi.org\/10.1016\/j.eururo.2014.01.006","journal-title":"Eur Urol"},{"key":"1884_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.07.027","author":"P Gontero","year":"2024","unstructured":"Gontero P, Birtle A, Capoun O, Comp\u00e9rat E, Dominguez-Escrig JL, Liedberg F et al (2024) European Association of Urology Guidelines on Non\u2013muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)\u2014A Summary of the 2024 Guidelines Update. Eur Urol. https:\/\/doi.org\/10.1016\/j.eururo.2024.07.027","journal-title":"Eur Urol"},{"key":"1884_CR7","doi-asserted-by":"publisher","first-page":"eabn4118","DOI":"10.1126\/scitranslmed.abn4118","volume":"15","author":"FC de Jong","year":"2023","unstructured":"de Jong FC, Laajala TD, Hoedemaeker RF, Jordan KR, van der Made ACJ, Boev\u00e9 ER et al (2023) Non-muscle-invasive bladder cancer molecular subtypes predict differential response to intravesical Bacillus Calmette-Gu\u00e9rin. Sci Transl Med 15:eabn4118. https:\/\/doi.org\/10.1126\/scitranslmed.abn4118","journal-title":"Sci Transl Med"},{"key":"1884_CR8","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/S0302-2838(03)00371-3","volume":"44","author":"RJ Sylvester","year":"2003","unstructured":"Sylvester RJ, van der Meijden APM, Oosterlinck W, Hoeltl W, Bono AV (2003) The Side Effects of Bacillus Calmette-Guerin in the Treatment of Ta T1 Bladder Cancer Do Not Predict its Efficacy: Results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol 44:423\u2013428. https:\/\/doi.org\/10.1016\/S0302-2838(03)00371-3","journal-title":"Eur Urol"},{"key":"1884_CR9","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.eururo.2014.11.031","volume":"67","author":"AH Mostafid","year":"2015","unstructured":"Mostafid AH, Palou Redorta J, Sylvester R, Witjes JA (2015) Therapeutic Options in High-risk Non\u2013muscle-invasive Bladder Cancer During the Current Worldwide Shortage of Bacille Calmette-Gu\u00e9rin. Eur Urol 67:359\u2013360. https:\/\/doi.org\/10.1016\/j.eururo.2014.11.031","journal-title":"Eur Urol"},{"key":"1884_CR10","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1158\/1078-0432.CCR-12-0077-T","volume":"18","author":"G Sj\u00f6dahl","year":"2012","unstructured":"Sj\u00f6dahl G, Lauss M, L\u00f6vgren K, Chebil G, Gudjonsson S, Veerla S et al (2012) A molecular taxonomy for urothelial carcinoma. Clin Cancer Res Off J Am Assoc Cancer Res 18:3377\u20133386. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-0077-T","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"1884_CR11","doi-asserted-by":"publisher","first-page":"4044","DOI":"10.1158\/1078-0432.CCR-04-2409","volume":"11","author":"E Blaveri","year":"2005","unstructured":"Blaveri E, Simko JP, Korkola JE, Brewer JL, Baehner F, Mehta K et al (2005) Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res Off J Am Assoc Cancer Res 11:4044\u20134055. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-2409","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"1884_CR12","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.eururo.2018.08.027","volume":"75","author":"TZ Tan","year":"2019","unstructured":"Tan TZ, Rouanne M, Tan KT, Huang RY-J, Thiery J-P (2019) Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors. Eur Urol 75:423\u2013432. https:\/\/doi.org\/10.1016\/j.eururo.2018.08.027","journal-title":"Eur Urol"},{"key":"1884_CR13","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/ng1061","volume":"33","author":"L Dyrskj\u00f8t","year":"2003","unstructured":"Dyrskj\u00f8t L, Thykjaer T, Kruh\u00f8ffer M, Jensen JL, Marcussen N, Hamilton-Dutoit S et al (2003) Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet 33:90\u201396. https:\/\/doi.org\/10.1038\/ng1061","journal-title":"Nat Genet"},{"key":"1884_CR14","doi-asserted-by":"publisher","first-page":"3463","DOI":"10.1158\/0008-5472.CAN-09-4213","volume":"70","author":"D Lindgren","year":"2010","unstructured":"Lindgren D, Frigyesi A, Gudjonsson S, Sj\u00f6dahl G, Hallden C, Chebil G et al (2010) Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res 70:3463\u20133472. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-4213","journal-title":"Cancer Res"},{"key":"1884_CR15","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1038\/s41467-021-22465-w","volume":"12","author":"SV Lindskrog","year":"2021","unstructured":"Lindskrog SV, Prip F, Lamy P, Taber A, Groeneveld CS, Birkenkamp-Demtr\u00f6der K et al (2021) An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. Nat Commun 12:2301. https:\/\/doi.org\/10.1038\/s41467-021-22465-w","journal-title":"Nat Commun"},{"key":"1884_CR16","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1038\/s41598-018-22126-x","volume":"8","author":"N-A-D Marzouka","year":"2018","unstructured":"Marzouka N-A-D, Eriksson P, Rovira C, Liedberg F, Sj\u00f6dahl G, H\u00f6glund M (2018) A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort. Sci Rep 8:3737. https:\/\/doi.org\/10.1038\/s41598-018-22126-x","journal-title":"Sci Rep"},{"key":"1884_CR17","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1093\/jnci\/djx243","volume":"110","author":"Q Mo","year":"2018","unstructured":"Mo Q, Nikolos F, Chen F, Tramel Z, Lee Y-C, Hayashi K et al (2018) Prognostic Power of a Tumor Differentiation Gene Signature for Bladder Urothelial Carcinomas. J Natl Cancer Inst 110:448\u2013459. https:\/\/doi.org\/10.1093\/jnci\/djx243","journal-title":"J Natl Cancer Inst"},{"key":"1884_CR18","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.eururo.2020.06.048","volume":"78","author":"AG Robertson","year":"2020","unstructured":"Robertson AG, Groeneveld CS, Jordan B, Lin X, McLaughlin KA, Das A et al (2020) Identification of Differential Tumor Subtypes of T1 Bladder Cancer. Eur Urol 78:533\u2013537. https:\/\/doi.org\/10.1016\/j.eururo.2020.06.048","journal-title":"Eur Urol"},{"key":"1884_CR19","unstructured":"Transparency (2025) In The reporting of Artificial INtelligence \u2013 the TITAN guideline - Premier Science. https:\/\/premierscience.com\/pjs-25-950\/. Accessed 8 July 2025"},{"key":"1884_CR20","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1093\/jnci\/dji237","volume":"97","author":"LM McShane","year":"2005","unstructured":"McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM et al (2005) Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK). JNCI J Natl Cancer Inst 97:1180\u20131184. https:\/\/doi.org\/10.1093\/jnci\/dji237","journal-title":"JNCI J Natl Cancer Inst"},{"key":"1884_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1476-4598-9-3","volume":"9","author":"W-J Kim","year":"2010","unstructured":"Kim W-J, Kim E-J, Kim S-K, Kim Y-J, Ha Y-S, Jeong P et al (2010) Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Mol Cancer 9:3. https:\/\/doi.org\/10.1186\/1476-4598-9-3","journal-title":"Mol Cancer"},{"key":"1884_CR22","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1137\/040608635","volume":"30","author":"S Van Dongen","year":"2008","unstructured":"Van Dongen S (2008) Graph Clustering Via a Discrete Uncoupling Process. SIAM J Matrix Anal Appl 30:121\u2013141. https:\/\/doi.org\/10.1137\/040608635","journal-title":"SIAM J Matrix Anal Appl"},{"key":"1884_CR23","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003234.16","author":"A Gabrielson","year":"2023","unstructured":"Gabrielson A, Epstein G, Feng M, Patel S, Kates M, Choi W, MP14-16 LATE CELL CYCLE SIGNATURES STRATIFY GEMDOCE RESPONSES FOR BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER (2023) J Urol. https:\/\/doi.org\/10.1097\/JU.0000000000003234.16","journal-title":"J Urol"},{"key":"1884_CR24","doi-asserted-by":"publisher","first-page":"i90","DOI":"10.1093\/jrr\/rrw007","volume":"57","author":"MR Horsman","year":"2016","unstructured":"Horsman MR, Overgaard J (2016) The impact of hypoxia and its modification of the outcome of radiotherapy. J Radiat Res (Tokyo) 57:i90\u2013i98. https:\/\/doi.org\/10.1093\/jrr\/rrw007","journal-title":"J Radiat Res (Tokyo)"},{"key":"1884_CR25","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.ijrobp.2004.03.005","volume":"59","author":"TM Pawlik","year":"2004","unstructured":"Pawlik TM, Keyomarsi K (2004) Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol 59:928\u2013942. https:\/\/doi.org\/10.1016\/j.ijrobp.2004.03.005","journal-title":"Int J Radiat Oncol"},{"key":"1884_CR26","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y et al (2018) TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554:544\u2013548. https:\/\/doi.org\/10.1038\/nature25501","journal-title":"Nature"},{"key":"1884_CR27","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/s41416-021-01488-6","volume":"125","author":"TL Rose","year":"2021","unstructured":"Rose TL, Weir WH, Mayhew GM, Shibata Y, Eulitt P, Uronis JM et al (2021) Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience. Br J Cancer 125:1251\u20131260. https:\/\/doi.org\/10.1038\/s41416-021-01488-6","journal-title":"Br J Cancer"},{"key":"1884_CR28","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1002\/1878-0261.13146","volume":"16","author":"JL Gulley","year":"2022","unstructured":"Gulley JL, Schlom J, Barcellos-Hoff MH, Wang X-J, Seoane J, Audhuy F et al (2022) Dual inhibition of TGF-\u03b2 and PD-L1: a novel approach to cancer treatment. Mol Oncol 16:2117\u20132134. https:\/\/doi.org\/10.1002\/1878-0261.13146","journal-title":"Mol Oncol"},{"key":"1884_CR29","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41585-024-00914-7","volume":"22","author":"M Olislagers","year":"2025","unstructured":"Olislagers M, de Jong FC, Rutten VC, Boormans JL, Mahmoudi T, Zuiverloon TCM (2025) Molecular biomarkers of progression in non-muscle-invasive bladder cancer \u2014 beyond conventional risk stratification. Nat Rev Urol 22:75\u201391. https:\/\/doi.org\/10.1038\/s41585-024-00914-7","journal-title":"Nat Rev Urol"},{"key":"1884_CR30","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD et al (2017) Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell 171:540\u2013556e25. https:\/\/doi.org\/10.1016\/j.cell.2017.09.007","journal-title":"Cell"},{"key":"1884_CR31","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13045-020-00937-8","volume":"13","author":"R Duan","year":"2020","unstructured":"Duan R, Du W, Guo W (2020) EZH2: a novel target for cancer treatment. J Hematol OncolJ Hematol Oncol 13:104. https:\/\/doi.org\/10.1186\/s13045-020-00937-8","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"1884_CR32","doi-asserted-by":"publisher","first-page":"3842","DOI":"10.3892\/ol.2018.9118","volume":"16","author":"L Guo","year":"2018","unstructured":"Guo L, Yin M, Wang Y (2018) CREB1, a direct target of miR-122, promotes cell proliferation and invasion in bladder cancer. Oncol Lett 16:3842\u20133848. https:\/\/doi.org\/10.3892\/ol.2018.9118","journal-title":"Oncol Lett"},{"key":"1884_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s42003-023-04561-3","volume":"6","author":"PY Guneri-Sozeri","year":"2023","unstructured":"Guneri-Sozeri PY, \u00d6zden-Y\u0131lmaz G, Kisim A, Cakiroglu E, Eray A, Uzuner H et al (2023) FLI1 and FRA1 transcription factors drive the transcriptional regulatory networks characterizing muscle invasive bladder cancer. Commun Biol 6:1\u201317. https:\/\/doi.org\/10.1038\/s42003-023-04561-3","journal-title":"Commun Biol"},{"key":"1884_CR34","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41588-024-02030-z","volume":"57","author":"F Prip","year":"2025","unstructured":"Prip F, Lamy P, Lindskrog SV, Strandgaard T, Nordentoft I, Birkenkamp-Demtr\u00f6der K et al (2025) Comprehensive genomic characterization of early-stage bladder cancer. Nat Genet 57:115\u2013125. https:\/\/doi.org\/10.1038\/s41588-024-02030-z","journal-title":"Nat Genet"},{"key":"1884_CR35","unstructured":"WISP. WISP (2025) https:\/\/cit-bioinfo.github.io\/WISP\/. Accessed 22 Jan"},{"key":"1884_CR36","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.eururo.2023.05.037","volume":"85","author":"CS Groeneveld","year":"2024","unstructured":"Groeneveld CS, Sanchez-Quiles V, Dufour F, Shi M, Dingli F, Nicolle R et al (2024) Proteogenomic Characterization of Bladder Cancer Reveals Sensitivity to Apoptosis Induced by Tumor Necrosis Factor\u2013related Apoptosis-inducing Ligand in FGFR3-mutated Tumors. Eur Urol 85:483\u2013494. https:\/\/doi.org\/10.1016\/j.eururo.2023.05.037","journal-title":"Eur Urol"},{"key":"1884_CR37","doi-asserted-by":"publisher","unstructured":"Taber A, Park Y, Lelo A, Prip F, Xiao J, Berry DL et al (2021) STAG2 as a prognostic biomarker in low-grade non-muscle invasive bladder cancer. Urol Oncol Semin Orig Investig 39. https:\/\/doi.org\/10.1016\/j.urolonc.2021.02.007. :438.e1-438.e9","DOI":"10.1016\/j.urolonc.2021.02.007"},{"key":"1884_CR38","doi-asserted-by":"publisher","first-page":"4145","DOI":"10.1158\/1078-0432.CCR-17-3244","volume":"24","author":"A Lelo","year":"2018","unstructured":"Lelo A, Prip F, Harris BT, Solomon D, Berry DL, Chaldekas K et al (2018) STAG2 Is a Biomarker for Prediction of Recurrence and Progression in Papillary Non\u2013Muscle-Invasive Bladder Cancer. Clin Cancer Res 24:4145\u20134153. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-3244","journal-title":"Clin Cancer Res"},{"key":"1884_CR39","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.eururo.2018.09.002","volume":"75","author":"EJ Pietzak","year":"2019","unstructured":"Pietzak EJ, Zabor EC, Bagrodia A, Armenia J, Hu W, Zehir A et al (2019) Genomic Differences Between Primary and Secondary Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy. Eur Urol 75:231\u2013239. https:\/\/doi.org\/10.1016\/j.eururo.2018.09.002","journal-title":"Eur Urol"},{"key":"1884_CR40","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.euros.2022.02.011","volume":"39","author":"NC Grossmann","year":"2022","unstructured":"Grossmann NC, Rajwa P, Quhal F, K\u00f6nig F, Mostafaei H, Laukhtina E et al (2022) Comparative Outcomes of Primary Versus Recurrent High-risk Non\u2013muscle-invasive and Primary Versus Secondary Muscle-invasive Bladder Cancer After Radical Cystectomy: Results from a Retrospective Multicenter Study. Eur Urol Open Sci 39:14\u201321. https:\/\/doi.org\/10.1016\/j.euros.2022.02.011","journal-title":"Eur Urol Open Sci"},{"key":"1884_CR41","doi-asserted-by":"publisher","first-page":"93e1","DOI":"10.1016\/j.urolonc.2017.09.027","volume":"36","author":"I Grenga","year":"2018","unstructured":"Grenga I, Donahue RN, Gargulak ML, Lepone LM, Roselli M, Bilusic M et al (2018) Anti-PD-L1\/TGF\u03b2R2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis. Urol Oncol 36:93e1. https:\/\/doi.org\/10.1016\/j.urolonc.2017.09.027","journal-title":"Urol Oncol"},{"key":"1884_CR42","doi-asserted-by":"publisher","unstructured":"Niglio SA, Girardi DdaM, Cordes LM, Ley L, Mallek M, Sierra Ortiz O et al (2021) A phase I study of bintrafusp alfa (M7824) and NHS-IL12 (M9241) alone and in combination with stereotactic body radiation therapy (SBRT) in adults with metastatic non-prostate genitourinary malignancies. J Clin Oncol. ;39 15_suppl:TPS4599\u2013TPS4599. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.TPS4599","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS4599"},{"key":"1884_CR43","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1002\/cac2.12602","volume":"44","author":"M Noeraparast","year":"2024","unstructured":"Noeraparast M, Krajina K, Pichler R, Nieders\u00fc\u00df-Beke D, Shariat SF, Gr\u00fcnwald V et al (2024) FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies. Cancer Commun 44:1189\u20131208. https:\/\/doi.org\/10.1002\/cac2.12602","journal-title":"Cancer Commun"},{"key":"1884_CR44","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.annonc.2023.09.3116","volume":"35","author":"JWF Catto","year":"2024","unstructured":"Catto JWF, Tran B, Roupr\u00eat M, Gschwend JE, Loriot Y, Nishiyama H et al (2024) Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer. Ann Oncol 35:98\u2013106. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.3116","journal-title":"Ann Oncol"},{"key":"1884_CR45","doi-asserted-by":"publisher","unstructured":"Vilaseca A, Guerrero F, Zainfeld D, Shore ND, Rodriguez Faba O, Meijer RP et al (2023) Safety and efficacy of the erdafitinib (erda) intravesical delivery system, TAR-210, in patients (pts) with non\u2013muscle-invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC) harboring select FGFR mutations or fusions: Phase 1 first-in-human study. J Clin Oncol. ;41 6_suppl:TPS583\u2013TPS583. https:\/\/doi.org\/10.1200\/JCO.2023.41.6_suppl.TPS583","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS583"},{"key":"1884_CR46","doi-asserted-by":"publisher","first-page":"e38863","DOI":"10.1371\/journal.pone.0038863","volume":"7","author":"D Lindgren","year":"2012","unstructured":"Lindgren D, Sj\u00f6dahl G, Lauss M, Staaf J, Chebil G, L\u00f6vgren K et al (2012) Integrated Genomic and Gene Expression Profiling Identifies Two Major Genomic Circuits in Urothelial Carcinoma. PLoS ONE 7:e38863. https:\/\/doi.org\/10.1371\/journal.pone.0038863","journal-title":"PLoS ONE"},{"key":"1884_CR47","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","volume":"25","author":"W Choi","year":"2014","unstructured":"Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J et al (2014) Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy. Cancer Cell 25:152\u2013165. https:\/\/doi.org\/10.1016\/j.ccr.2014.01.009","journal-title":"Cancer Cell"},{"key":"1884_CR48","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/path.4886","volume":"242","author":"G Sj\u00f6dahl","year":"2017","unstructured":"Sj\u00f6dahl G, Eriksson P, Liedberg F, H\u00f6glund M (2017) Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification. J Pathol 242:113\u2013125. https:\/\/doi.org\/10.1002\/path.4886","journal-title":"J Pathol"},{"key":"1884_CR49","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ebiom.2019.10.058","volume":"50","author":"B-N Song","year":"2019","unstructured":"Song B-N, Kim S-K, Mun J-Y, Choi Y-D, Leem S-H, Chu I-S (2019) Identification of an immunotherapy-responsive molecular subtype of bladder cancer. EBioMedicine 50:238\u2013245. https:\/\/doi.org\/10.1016\/j.ebiom.2019.10.058","journal-title":"EBioMedicine"},{"key":"1884_CR50","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1002\/ijc.32737","volume":"146","author":"G Sj\u00f6dahl","year":"2020","unstructured":"Sj\u00f6dahl G, Eriksson P, Patschan O, Marzouka N-A-D, Jakobsson L, Bernardo C et al (2020) Molecular changes during progression from nonmuscle invasive to advanced urothelial carcinoma. Int J Cancer 146:2636\u20132647. https:\/\/doi.org\/10.1002\/ijc.32737","journal-title":"Int J Cancer"},{"key":"1884_CR51","doi-asserted-by":"publisher","first-page":"100472","DOI":"10.1016\/j.xcrm.2021.100472","volume":"2","author":"CD Hurst","year":"2021","unstructured":"Hurst CD, Cheng G, Platt FM, Castro MAA, Marzouka NS, Eriksson P et al (2021) Stage-stratified molecular profiling of non-muscle-invasive bladder cancer enhances biological, clinical, and therapeutic insight. Cell Rep Med 2:100472. https:\/\/doi.org\/10.1016\/j.xcrm.2021.100472","journal-title":"Cell Rep Med"},{"key":"1884_CR52","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1158\/1078-0432.CCR-11-2271","volume":"18","author":"M Riester","year":"2012","unstructured":"Riester M, Taylor JM, Feifer A, Koppie T, Rosenberg JE, Downey RJ et al (2012) Combination of a Novel Gene Expression Signature with a Clinical Nomogram Improves the Prediction of Survival in High-Risk Bladder Cancer. Clin Cancer Res 18:1323\u20131333. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-2271","journal-title":"Clin Cancer Res"},{"key":"1884_CR53","doi-asserted-by":"publisher","first-page":"9743","DOI":"10.1038\/s41598-020-66747-7","volume":"10","author":"CC Guo","year":"2020","unstructured":"Guo CC, Bondaruk J, Yao H, Wang Z, Zhang L, Lee S et al (2020) Assessment of Luminal and Basal Phenotypes in Bladder Cancer. Sci Rep 10:9743. https:\/\/doi.org\/10.1038\/s41598-020-66747-7","journal-title":"Sci Rep"}],"container-title":["Functional & Integrative Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10142-026-01884-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10142-026-01884-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10142-026-01884-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T04:49:23Z","timestamp":1778906963000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10142-026-01884-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,16]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1884"],"URL":"https:\/\/doi.org\/10.1007\/s10142-026-01884-2","relation":{},"ISSN":["1438-793X","1438-7948"],"issn-type":[{"value":"1438-793X","type":"print"},{"value":"1438-7948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,16]]},"assertion":[{"value":"3 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors claim no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"103"}}